{
  "nct_id": "NCT63401626",
  "indication": "Prostate Cancer",
  "phase": "Phase 3",
  "sample_size": 782,
  "duration_weeks": 26,
  "dropout_rate": 0.11,
  "blinding": "double-blind",
  "control_arm": "placebo",
  "primary_endpoints": [
    "PSA response"
  ],
  "secondary_endpoints": [
    "Overall survival",
    "Time to PSA progression"
  ],
  "outcome_summary": "Did not meet primary efficacy endpoints",
  "success": 0,
  "failure_reason": "Dose selection suboptimal",
  "start_date": "2023-01-30",
  "completion_date": "2023-07-31"
}